Publications by authors named "Marion Afonso"

Introduction: Pompe disease is caused by a rare biallelic mutation in the GAA gene resulting in acid α-glucosidase deficiency and glycogen accumulation.

Aim: We analyzed hospital admissions associated with the administration of Myozyme®, utilizing the French hospital discharge database, known in France as the Programme de Médicalisation des Systèmes d'Information (PMSI), which comprehensively captures all hospital activity within the country.

Methods: In this observational study, we examined hospitalization records from April 4, 2012, to December 31, 2019, within the PMSI database, focusing on admissions where Myozyme® was administered.

View Article and Find Full Text PDF

Introduction: An evolving haemophilia treatment landscape provides new possibilities for previously unattainable lifestyles.

Aim: We sought to understand how people with haemophilia (PwH) and their caregivers value the potential benefits of novel prophylactic treatments. We conducted a discrete-choice experiment (DCE) to quantify preferences for features of haemophilia treatments among adults and caregivers of children with haemophilia.

View Article and Find Full Text PDF
Article Synopsis
  • Diabetes-related distress is prevalent among individuals with diabetes and negatively impacts both glycemic control and overall health, making it an important patient-reported outcome (PRO).
  • A study analyzing data from adults with type 1 diabetes (T1D) using sotagliflozin alongside insulin found that a higher percentage of patients reported significant improvements in treatment satisfaction compared to those on placebo.
  • Overall, patients taking sotagliflozin experienced notable reductions in both diabetes distress and improvements in treatment satisfaction, highlighting its potential benefits in diabetes management.
View Article and Find Full Text PDF

Objectives: This study investigated the cost per responder and number needed to treat (NNT) in type 2 diabetes mellitus (T2DM) patients for lixisenatide compared to insulin intensification regimens using composite endpoints in the UK, Italy, and Spain.

Methods: Efficacy and safety outcomes were obtained from GetGoal Duo-2, a 26-week phase 3 trial comparing lixisenatide vs insulin glulisine (IG) once daily (QD) and three times daily (TID). Response at week 26 was extrapolated to 52 weeks, assuming a maintained treatment effect, based on long-term evidence in other T2DM populations.

View Article and Find Full Text PDF

A PHP Error was encountered

Severity: Warning

Message: fopen(/var/lib/php/sessions/ci_session00a1shf4hu8brrat4675kqe7gf4e0o0s): Failed to open stream: No space left on device

Filename: drivers/Session_files_driver.php

Line Number: 177

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: session_start(): Failed to read session data: user (path: /var/lib/php/sessions)

Filename: Session/Session.php

Line Number: 137

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once